Right ventricular pressure and dilation during pressure overload determine dysfunction after pressure overload.
Volume expansion and inotropic stimulation are used clinically to augment cardiac output during acute right ventricular (RV) pressure overload. We previously showed that a brief period of RV pressure overload causes RV free wall dysfunction that persists after normal loading conditions have been restored. However, the impact of volume expansion and inotropic stimulation on the severity of RV dysfunction after acute pressure overload is unknown. We hypothesized that the severity of RV dysfunction after RV pressure overload would be related to the level of RV free wall systolic stress during RV pressure overload, rather than to the specific interventions used to augment RV function. Chloralose-anesthetized, open-chest pigs were subjected to 1 h of RV pressure overload caused by pulmonary artery constriction, followed by 1 h of recovery after release of pulmonary artery constriction. A wide range of RV free wall systolic stress during RV pressure overload was achieved by either closing or opening the pericardium (to simulate volume expansion) and by administering or not administering dobutamine. The severity of RV free wall dysfunction 1 h after RV pressure overload was strongly and directly correlated with the values of two hemodynamic variables during RV pressure overload: RV free wall area at peak RV systolic pressure (determined by sonomicrometry) and peak RV systolic pressure, two of the major determinants of peak RV free wall systolic stress. Opening or closing the pericardium, and using or not using dobutamine during RV pressure overload, had no independent effects on the severity of RV dysfunction. The findings suggest that the goal of therapeutic intervention during RV pressure overload should be to achieve the required augmentation of cardiac output with the smallest possible increase in RV free wall systolic stress.
Greyson
C
C
Cardiology Section, Department of Veterans Affairs Medical Center, University of Colorado Health Sciences Center, Denver, Colorado 80220, USA. Clifford.Greyson@UCHSC.edu
Xu
Y
Y
Lu
L
L
Schwartz
G G
GG
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D006328:Cardiac Catheterization / Q000295:instrumentation; D002316:Cardiotonic Agents / Q000494:pharmacology; D002317:Cardiovascular Agents / Q000494:pharmacology; D003971:Diastole / Q000187:drug effects; D004108:Dilatation, Pathologic / Q000503:physiopathology; D004195:Disease Models, Animal; D004280:Dobutamine / Q000494:pharmacology; D005260:Female; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D018738:Hexamethonium / Q000494:pharmacology; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D016014:Linear Models; D010496:Pericardium / Q000601:surgery; D011651:Pulmonary Artery / Q000503:physiopathology / Q000601:surgery; D013552:Swine; D013599:Systole / Q000187:drug effects; D018497:Ventricular Dysfunction, Right / Q000188:drug therapy / Q000503:physiopathology*
D002316:Cardiotonic Agents; D002317:Cardiovascular Agents; D018738:Hexamethonium; D004280:Dobutamine; D001285:Atropine